Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals)

93 articles about Kadmon Corporation (Formerly Known As Kadmon Pharmaceuticals)

• 

  BioSpace Movers and Shakers: Feb. 15

  2/15/2019

  Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.

• Kadmon Provides Business Update and Reports Second Quarter 2018 Financial Results

  8/9/2018

  Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the second quarter of 2018.

• Kadmon Announces Updated Results of KD025 in cGVHD at EHA Congress

  6/15/2018

  Results from the study will be presented in an oral session on Saturday, June 16th, 2018 at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden.

• Kadmon Announces Proposed Public Offering of Common Stock

  6/11/2018

  Kadmon Corporation, Inc. (NYSE:KDMN) today announced its intention to offer and sell shares of its common stock in a public offering pursuant to an existing shelf registration statement. T

• Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease

  4/10/2018

  Based on the FDA’s guidance, Kadmon plans to initiate an open-label, two-arm, pivotal Phase 2 clinical trial to support the potential registration of KD025 in cGVHD.

• Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2017 Financial Results

  3/6/2018

  Kadmon Holdings, Inc. provided an update on upcoming milestones and recent achievements, and reported financial and operational results for the fourth quarter and full year ended December 31, 2017.

• Distributed Bio Announces SuperHuman Platform Transfer to Kadmon

  2/28/2018

  Agreement with Kadmon Corporation , LLC to license the Distributed Bio SuperHuman Platform for accelerating the discovery of antibody-based drugs.

• Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF

  2/13/2018

  Kadmon today announced that it will hold a webcast and conference call tomorrow, February 13, 2018, at 8:30 a.m. ET.

• Kadmon Announces Positive Topline Results from Phase II Study of KD025 in Idiopathic Pulmonary Fibrosis

  2/13/2018

  Kadmon today announced topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib.

• Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting

  12/11/2017

  Kadmon announced additional positive findings from an ongoing Phase 2 clinical trial demonstrating that KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, was well tolerated and resulted in clinically meaningful responses in patients with chronic graft-versus-host disease (cGVHD).

• Kadmon Initiates Phase II Placebo-Controlled Clinical Trial of Tesevatinib in Autosomal Dominant Polycystic Kidney Disease

  11/13/2017

  The primary endpoint is the change from baseline in height-adjusted total kidney volume at 12 months.

• Kadmon Provides Business Update and Reports Third Quarter 2017 Financial Results

  11/10/2017

  Loss from operations for the three and nine months ended September 30, 2017 was $19.8 million and $51.4 million, respectively, compared to $53.1 million and $95.8 million for the respective periods in 2016.

• Kadmon to Present New Data From Ongoing Phase II Study of KD025 in cGVHD at ASH Annual Meeting

  11/2/2017

  The data will be presented as a poster at the 59th ASH Annual Meeting in Atlanta, December 9-12, 2017.

• FDA Grants Orphan Drug Designation To Kadmon’s KD025 For The Treatment Of cGVHD

  10/6/2017

• Kadmon Announces Closing Of $80.4 Million Public Offerings And Full Exercise Of Over-Allotment Option

  9/28/2017

• Kadmon Announces Proposed Public Offering Of Common Stock And Warrants

  9/26/2017

• Kadmon To Present Preclinical Data On ROCK Inhibition In Pulmonary Fibrosis At IPF Summit 2017

  8/11/2017

• FDA Grants Orphan Drug Designation To Kadmon’s Tesevatinib For The Treatment Of EGFR-Mutated Non-Small Cell Lung Cancer

  8/7/2017

• Kadmon Provides Business Update and Reports Second Quarter 2017 Financial Results

  8/4/2017

• Kadmon Announces Supplemental Interim Phase II Data Of KD025 In Chronic Graft-Versus-Host Disease

  7/25/2017